Trial Profile
An open, single dose, antitumor effect study of 2-hydroxyflutamide as a controlled release product (Liproca Depot), injected into the prostate in patients with localized prostate cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Hydroxyflutamide (Primary)
- Indications Prostate cancer
- Focus Pharmacodynamics
- Sponsors LIDDS
- 08 Feb 2018 According to a Lidds Pharma media release, results from this and the LPC-002 trials have been published in The Journal of Urology in December 2016.
- 10 Mar 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 13 Jan 2015 Planned End Date changed from 21 Feb 2012 to 1 May 2016, according to ClinicalTrials.gov record.